Clinical Trial Update: Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of olaparib and durvalumab in IDH-mutated solid tumors, including glioma and cholangiocarcinoma, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Glioma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Glioma, Cholangiocarcinoma | Phase 2 | Status: RECRUITING